Roivant Sciences Director Melissa Epperly Exercises and Sells Shares via 10b5-1 Plan

Executive Summary

On October 1, 2026, Melissa B. Epperly, a Director of Roivant Sciences Ltd. ($ROIV), executed a pre-scheduled exercise and sale transaction under a Rule 10b5-1 trading plan adopted on March 30, 2026. The director exercised stock options for 17,750 common shares at an exercise price of $4.46 per share and simultaneously sold the entirety of the acquired shares across two open-market transactions for total gross proceeds of approximately $640,861.

Transaction Breakdown

• Option Exercise (Code M): 17,750 shares acquired via stock option exercise at $4.46 per share (cost basis: $79,165).
• Open Market Sales (Code S):
  • 16,850 shares sold at a weighted average price of $36.08 ($35.46 – $36.45).
  • 900 shares sold at a weighted average price of $36.57 ($36.48 – $36.72).
  • Combined Proceeds: ~$640,861 (average sale price of ~$36.10).
• Net Cash Realized: ~$561,696 before taxes and fees.

Holdings Analysis

Following the transactions:

• Direct common shares owned stand at 14,954, unchanged from her baseline direct holding prior to the exercise.
• Derivative holdings: 151,416 stock options remaining under the same award grant (expiring July 19, 2032).

Market Impact & Significance

This transaction carries Low informational significance. It represents a standard exercise-and-sell operation pursuant to a pre-established Rule 10b5-1 plan established over six months prior, leaving her pre-existing direct share ownership intact while converting a small portion of fully vested stock options into cash.